Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
M Santarpia, A Liguori, N Karachaliou… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy
T Nagano, M Tachihara, Y Nishimura - Cells, 2018 - mdpi.com
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
YN Lamb - Targeted oncology, 2021 - Springer
Activating mutations in the epidermal growth factor receptor (EGFR) gene have been
identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib …
identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib …
Postprogression outcomes for osimertinib versus standard-of-care egfr-tki in patients with previously untreated egfr-mutated advanced non–small cell lung cancer
D Planchard, MJ Boyer, JS Lee, A Dechaphunkul… - Clinical Cancer …, 2019 - AACR
Purpose: In the phase III FLAURA study, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
[HTML][HTML] A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
A Russo, T Franchina, GRR Ricciardi, A Picone… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …
[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
9507 Background: First-line treatment with an EGFR tyrosine kinase inhibitor (TKI) is
standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is …
standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is …